Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1136-1141

  Kehrer, Diederik F S ^a   Sparreboom, Alex ^a   Verweij, Jaap ^a   De Bruijn, Peter ^a   Nierop, Corine A ^a   Van de Schraaf, Jacqueline ^a   Ruijgrok, Elisabeth J ^a   De Jonge, Maja J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GLUCURONIDASE; IRINOTECAN; NEOMYCIN; PHENOLPHTHALEIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONCENTRATION RESPONSE; DIARRHEA; DRUG DISPOSITION; ENZYME ACTIVITY; FECES ANALYSIS; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CROSS-OVER STUDIES; DIARRHEA; HUMANS; MIDDLE AGED; NEOMYCIN; NEOPLASMS;

EID: 0034901949     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
2. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
3. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
4. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
5. Topoisomerase I inhibitors: Topotecan and irinotecan
6. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
7. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
8. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
9. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent irinotecan hydrochloride (CPT-11) in rats
10. Antimicrobial agents neomycin
11. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine, and feces
12. Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
13. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
14. Irinotecan (CPT-11) metabolism and disposition in cancer patients
15. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials
16. Intravenous administration of irinotecan elevates the blood β-glucuronidase activity in rats
17. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
18. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection
19. Protective effects of kampo medicines and baicalin against intestinal toxicity of the new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
20. Reduction by hange-shashin-to (TJ-14), a herbal medicine on gastrointestinal tract complications induced by CPT-11 containing chemotherapy